[Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly]
- PMID: 19040034
[Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly]
Abstract
Objective: To compare the safety and immunogenicity between a MF59-adjuvanted influenza subunit vaccine and a conventional non-adjuvanted influenza subunit vaccine.
Methods: A randomized, blind-designed controlled study was carried out, with 600 subjects (> or = 60 years of age) received MF59-adjuvanted influenza subunit vaccine (FLUAD, n = 400) or conventional non-adjuvanted influenza subunit vaccine (Agrippal, n = 200) respectively. The local and systemic reactions were observed on 0-7 days after vaccination. Haemagglutination inhibition (HI) titers of pre-and post-vaccination were detected by the HI assay. Seroconversion (4-fold increase) rate of subjects was calculated using baseline data when it was under naive level, and the protection rate when HI titer achieving the level of protection (> or = 1:40) after vaccination. Geometric mean titer (GMT) and its increasing folds were calculated. Differences between safety and immunogenicity were also calculated.
Results: The local and systemic reaction rates were similar between both groups, but the duration in injection site was frequent for Agrippal (P < 0.05), while mild pain and fever in injection site were frequent for FLUAD. On immunogenicity test, for those subjects whose baseline was under naive level while the seroconversion rate against A/H3N2 viral strain after vaccination--FLUAD was significantly higher than Agrippal (P < 0.001). Aside from A/H1N1 viral strain, the rate of protection on both groups were significantly higher than those from baseline data, but for A/H3N2 viral strain, FLUAD was significantly higher than Agrippal (P < 0.001). GMT was higher than baseline (P < 0.001) after both groups being vaccinated but FLUAD group was significantly higher than Agrippal group.
Conclusion: FLUAD was well tolerated by Chinese elderly and its immunogenicity level induced by FLUAD was higher than that of Agrippal, showing that it would benefit the elderly with hypoimmunity.
Similar articles
-
Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.J Prev Med Hyg. 2009 Jun;50(2):121-6. J Prev Med Hyg. 2009. PMID: 20099444
-
[Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].Zhonghua Liu Xing Bing Xue Za Zhi. 2003 Jul;24(7):570-3. Zhonghua Liu Xing Bing Xue Za Zhi. 2003. PMID: 12975010 Clinical Trial. Chinese.
-
MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.Vaccine. 2007 May 16;25(20):3955-61. doi: 10.1016/j.vaccine.2007.02.045. Epub 2007 Mar 6. Vaccine. 2007. PMID: 17383057 Clinical Trial.
-
MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.Expert Rev Vaccines. 2007 Oct;6(5):659-65. doi: 10.1586/14760584.6.5.659. Expert Rev Vaccines. 2007. PMID: 17931147 Review.
-
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.Expert Rev Vaccines. 2007 Oct;6(5):699-710. doi: 10.1586/14760584.6.5.699. Expert Rev Vaccines. 2007. PMID: 17931151 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical